Klinik für Urologie Tübingen



2014 Best Papers in Robotic Cystectomy

Dr Allen Sim







Introduction

 Over 100 publications since introduction of robotic cystectomy in 2003

30+ publications in 2014 alone

Important Issues

- •Is it effective?
- •Is it safe?
- Intracorporeal vs extracorporeal
- •Is it cost-effective?
- •How is the quality of life?





available at www.sciencedirect.com

journal homepage: www.europeanurology.com





Bladder Cancer

Robotic and Laparoscopic Radical Cystectomy for Bladder Cancer: Long-term Oncologic Outcomes

Devon C. Snow-Lisy^a, Steven C. Campbell^a, Inderbir S. Gill^b, Adrian V. Hernandez^c, Amr Fergany^a, Jihad Kaouk^a, Georges-Pascal Haber^{a,*}

^{*}Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA; *USC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA; *Department of Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA

- Retrospective study of 121 patients undergoing LRC (n=104) or RARC (n=17)
- Length of follow up 12 years
- Extracorporeal urinary diversion performed with ~
 70% ileal conduit
- Comparable oncologic outcomes to ORC in terms of LN yield, positive surgical margins.
- Many limitations to the study but it provides a good platform for future studies



- Previous randomized studies of open vs robotic cystectomy has shown lower blood loss, shorter hospital stay and less transfusion in the robotic groups* with similar oncologic outcomes and morbidity.
- Extracorporeal urinary diversion

Nix J, Smith A, Kurpad R et al: Prospective randomized trial of robotic versus open radical cystecomy for bladder cancer: perioperative and pathologic results Eur Urol 2010;57:196



^{*}Parekh DJ, Messer J, Fitzgerald J, Ercole B, Svatek R. Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. J Urol. 2013 Feb;189(2):474-9.



How about intracorporeal diversion?

ROBOTIC INTRACORPOREAL ORTHOTOPIC NEOBLADDER DURING RADICAL CYSTECTOMY IN 132 PATIENTS

- Wiklund et al reported combined experience of RARC with intracorporeal neobladder in 136 patients
- Comparable oncologic outcomes 1 patient with positive soft-tissue margin, median LN yield of 29 and CSS/OS over 70%
- 5 cases (3.8%) of benign ureteric stricture which is lower than contemporary open or robotic extracorporeal series
- Good functional outcomes 84% daytime and nighttime continence and 81% potent after undergoing nerve-sparing surgery



- The authors attributed the lower stricture rates to the theoritical advantage of intracorporeal diversion:
 - Minimum ureteral length
 - No need for extra mobilization of ureter
 - Less redundancy or kinking of ureter





Intracorporeal vs extracorporeal

EUROPEAN UROLOGY 65 (2014) 340-347

available at www.sciencedirect.com journal homepage: www.europeanurology.com





Platinum Priority - Bladder Cancer Editorial by Matthew Brown and Benjamin Challacombe on pp. 348-349 of this issue

Analysis of Intracorporeal Compared with Extracorporeal Urinary Diversion After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium





IRCC (International Radical Cystectomy Consortium)

- Initially known as International Robotic Cystectomy Consortium
- First formed in 2006 with 4 participating institutions, with pooled database of 162 patients
- Objective is to have better understanding of outcomes of RARC in a larger cohort of patients
- Currently, IRCC has expanded to 15 countries with 33 participating institutions and over 1400 patients.



Intracorporeal vs extracorporeal?

- Retrospective study
- 935 patients from 18 institutions underwent RARC from 2003 to 2011.
- 768 had ECUD (570 ileal conduits and 198 neobladders)
- 167 ICUD (106 conduits and 61 neobladders)





- Median follow up 9 months
- Comparable perioperative parameters such as operative time, blood loss and length of stay
- No significant difference in high-grade complications between the groups





Table 3 - Complications according to the organ system involved

Complication category, no. (%)	All	ECUD	ICUD	p value
Gastrointestinal*	161 (20)	142 (23)	19 (10)	< 0.001
Infection	136 (17)	114 (18)	22 (12)	0.035
Turing winner,	(-)	(-)	()	
General	30 (4)	27 (4)	3 (2)	0.119
Wound/skin	42 (5)	35 (6)	7 (4)	0.353
Hematologic/vascular	75 (9)	56 (9)	19 (10)	0.667
Pulmonary	24(3)	21 (3)	3 (2)	0.324
Metabolic	8(1)	8 (1)	0	0.209
Endocrine	3 (0.4)	2 (0.3)	1 (0.5)	0.546
Head/neck	4 (0.5)	3 (0.5)	1 (0.5)	1.000

ECUD = extracorporeal urinary diversion; ICUD = intracorporeal urinary diversion.





Defined as "acute abdomen whether resulting from a mechanical or nonmechanical cause. It also includes other complications like injuries, strictures, ischemia, perforations and leakages from anastomotic sites."

 ICUD technique is hypothesized to reduce fluid loss from intestines and minimizes trauma and resultant wall edema to the intestinal wall (secondary to its handling, retraction and mobilization)

Perioperative blood transfusion rate also lower in ICUD group





Morbidity & Cost-effectiveness

EUROPEAN UROLOGY 66 (2014) 569-576

available at www.sciencedirect.com journal homepage: www.europeanurology.com





Bladder Cancer

Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States


Jeffrey J. Leow a,b, Stephen W. Reese a,b, Wei Jiang a, Stuart R. Lipsitz a, Joaquim Bellmunt C, Quoc-Dien Trinh a,b,c, Benjamin I. Chung d, Adam S. Kibel b,c, Steven L. Chang a,b,c,*

^a Genter for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ^b Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ^c Dana-Farber/Brigham and Women's Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; ^d Department of Urology, Stanford University Medical Center, Stanford, CA, USA

 36773 patients who underwent either ORC or RARC in 279 hospitals from 2004 to 2010

 No significant differences in terms of major complications, mortaility and readmissions with lower minor complications (clavien grade I & II) and shorter LOS (1.51 days shorter) in RARC group








NO cost difference between RARC and ORC in subgroup analysis of highest-volume surgeons (≥7 cases per year) and highest-volume hospitals (≥19 cases per year)

Reducing either operating time or LOS substantially decrease cost of RARC







Lastly.....

- Evaluation of health-related quality of life (HRQL) using validated bladder-specific Bladder Cancer Index (BCI) and EORTC Body Image Scale (BIS) between ORC and RARC*
- RARC has comparable outcomes to ORC using BCI and BIS.
- Diversion technique does not affect patients' QOL

*Aboumohamed AA, Raza SJ, Al-Daghmin A, Tallman C, Creighton T, Crossley H, Dailey S, Khan A, Din R, Mehedint D, Wang K, Shi Y, Sharif M, Wilding G, Weizer A, Guru KA. Health-related quality of life outcomes after robot-assisted and open radical cystectomy using a validated bladder-specific instrument: a multi-institutional study. Urology 2014 Jun;83:1300-8.



Take Home Messages.....

- RARC is comparable to 'gold standard' ORC in terms of oncologic and functional outcomes
- Also comparable in terms of morbidity and mortality
- Superior in terms of blood loss and hospital stay
- Intracorporeal urinary diversion (ICUD) superior to extracorporeal urinary diversion (ICUD) in terms of lower bowel and wound complications
- RARC more costly than ORC unless done in high volume centers
- Similar HRQL between RARC and ORC



References:

- Snow-Lisy DC, Campbell SC, Gill IS, Hernandez AV, Fergany A, Kaouk J, Haber GP. Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes. Eur Urol. Jan 2014; 65:193-200
- Desai MM, Gill IS, de Castro Abreu AL, Hosseini A, Nyberg T, Adding C, Laurin O, Collins J, Miranda G, Goh A, Aron M, Wiklund P. Robotic Intracorporeal Orthotopic Neobladder During Radical Cystectomy in 132 Patients. J Urol. 2014 Jul. doi: 10.1016/j.juro.2014.06.087.
- 3. Ahmed K, Khan SA, Hayn MH, Agarwal PK, Badani KK, Balbay MD, Castle EP, Dasgupta P, Ghavamian R, Guru KA, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Redorta JP, Rha KH, Richstone L, Saar M, Scherr DS, Siemer S, Stoeckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Khan MS. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2014 Feb;65:340-7.
- 4. Leow JJ, Reese SW, Jiang W, Lipsitz SR, Bellmunt J, Trinh QD, Chung BI, Kibel AS, Chang SL. Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. Eur Urol 2014 Jan. doi: 10.1016/j.eururo.2014.01.029.
- 5. Aboumohamed AA, Raza SJ, Al-Daghmin A, Tallman C, Creighton T, Crossley H, Dailey S, Khan A, Din R, Mehedint D, Wang K, Shi Y, Sharif M, Wilding G, Weizer A, Guru KA. Health-related quality of life outcomes after robot-assisted and open radical cystectomy using a validated bladder-specific instrument: a multi-institutional study. Urology 2014 Jun;83:1300-8.





Acknowledgement

Prof. Christian Schwentner



